[Form 4] Helix Acquisition Corp. II Insider Trading Activity
Mark C. McKenna filed a Form 4 reporting ownership changes tied to the business combination and domestication of Helix Acquisition Corp. II into the issuer, which is identified here as BridgeBio Oncology Therapeutics, Inc. [BBOT]. On 08/11/2025 McKenna's 30,000 Helix shares were converted through a one-for-one exchange of Class B ordinary shares into Class A ordinary shares and then into the issuer's common stock, resulting in 30,000 common shares beneficially owned, held directly. The filing shows the conversion occurred at $0 consideration as part of the corporate reorganization. The filer also resigned as a director of Helix effective the same date immediately prior to the domestication.
Mark C. McKenna ha presentato un Modulo 4 segnalando variazioni nella titolarit脿 connesse alla business combination e alla domestication di Helix Acquisition Corp. II nell'emittente, identificata qui come BridgeBio Oncology Therapeutics, Inc. [BBOT]. In data 08/11/2025 le 30,000 azioni Helix di McKenna sono state convertite tramite uno scambio uno-a-uno da azioni ordinarie di Classe B in azioni ordinarie di Classe A e quindi in azioni ordinarie dell'emittente, con conseguente possesso beneficiario diretto di 30,000 azioni ordinarie. La comunicazione indica che la conversione 猫 avvenuta con una controprestazione pari a $0 nell'ambito della riorganizzazione societaria. Il dichiarante si 猫 inoltre dimesso dalla carica di direttore di Helix con effetto dalla medesima data, immediatamente prima della domestication.
Mark C. McKenna present贸 un Formulario 4 informando cambios en la propiedad vinculados a la combinaci贸n empresarial y la domestication de Helix Acquisition Corp. II en la emisora, identificada aqu铆 como BridgeBio Oncology Therapeutics, Inc. [BBOT]. El 08/11/2025 las 30,000 acciones de Helix de McKenna se convirtieron mediante un intercambio uno a uno de acciones ordinarias Clase B a Clase A y luego en acciones comunes de la emisora, resultando en la posesi贸n beneficiaria directa de 30,000 acciones comunes. La presentaci贸n indica que la conversi贸n se realiz贸 por una contraprestaci贸n de $0 como parte de la reorganizaci贸n corporativa. El declarante tambi茅n renunci贸 como director de Helix con efecto en la misma fecha, inmediatamente antes de la domestication.
Mark C. McKenna電� 氚滍枆須岇偓(鞐赴靹滊姅 BridgeBio Oncology Therapeutics, Inc. [BBOT])鞐� Helix Acquisition Corp. II鞚� 靷梾 瓴绊暕 氚� domestication瓿� 甏�霠悳 靻岇湢甓� 氤�瓴� 靷暛鞚� 氤搓碃頃橂姅 鞏戩嫕 4毳� 鞝滌稖頄堨姷雼堧嫟. 08/11/2025鞐� McKenna臧� 氤挫湢頃� Helix 欤检嫕 30,000欤茧姅 韥措灅鞀� B 氤错喌欤检棎靹� 韥措灅鞀� A 氤错喌欤茧 1:1 甑愴櫂霅� 頉� 氚滍枆須岇偓鞚� 氤错喌欤茧 鞝勴櫂霅橃柎, 攴� 瓴瓣臣 30,000欤检潣 氤错喌欤茧ゼ 歆侅爲鞝伮缝嫟歆堨爜鞙茧 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 鞚� 鞝勴櫂鞚� 須岇偓 鞛幐鞚� 鞚柬櫂鞙茧 $0鞚� 雽�臧�搿� 鞚措（鞏挫雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 鞝滌稖鞚胳潃 domestication 歆侅爠鞚� 臧欖潃 雮犾攵�搿� Helix鞚� 鞚挫偓歆侅棎靹� 靷瀯頄堨姷雼堧嫟.
Mark C. McKenna a d茅pos茅 un Formulaire 4 d茅clarant des changements de d茅tention li茅s 脿 la business combination et 脿 la domestication de Helix Acquisition Corp. II au sein de l'茅metteur, identifi茅 ici comme BridgeBio Oncology Therapeutics, Inc. [BBOT]. Le 08/11/2025, les 30,000 actions Helix de McKenna ont 茅t茅 converties via un 茅change un pour un d'actions ordinaires de classe B en actions ordinaires de classe A puis en actions ordinaires de l'茅metteur, ce qui aboutit 脿 la d茅tention b茅n茅ficiaire directe de 30,000 actions ordinaires. Le d茅p么t indique que la conversion a eu lieu pour une contrepartie de $0 dans le cadre de la r茅organisation d'entreprise. Le d茅clarant a 茅galement d茅missionn茅 de son poste d'administrateur de Helix 脿 la m锚me date, imm茅diatement avant la domestication.
Mark C. McKenna reichte ein Formular 4 ein, in dem 脛nderungen der Beteiligung im Zusammenhang mit der Business Combination und der domestication von Helix Acquisition Corp. II in den Emittenten, hier bezeichnet als BridgeBio Oncology Therapeutics, Inc. [BBOT], gemeldet werden. Am 08/11/2025 wurden McKennas 30,000 Helix-Aktien im Rahmen eines Eins-zu-eins-Tauschs von Class-B-Stammaktien in Class-A-Stammaktien und anschlie脽end in Stammaktien des Emittenten umgewandelt, wodurch er 30,000 vorteilhaft gehaltene Stammaktien direkt besitzt. Die Einreichung weist aus, dass die Umwandlung im Zuge der Unternehmensreorganisation ohne Gegenleistung in H枚he von $0 erfolgte. Der Einreicher trat au脽erdem mit Wirkung zum selben Datum, unmittelbar vor der domestication, als Direktor von Helix zur眉ck.
- 30,000 shares remain beneficially owned directly by the reporting person after conversion.
- One-for-one conversion of Class B to Class A and then to common stock was completed as part of the domestication with $0 cash consideration, reflecting a structural reclassification rather than a sale.
- Resignation from director role effective 08/11/2025, immediately prior to the domestication.
- Class B derivative holdings were converted and show 0 derivative securities remaining following the transaction.
Insights
TL;DR: Routine conversion of pre-existing Class B shares to common stock; reporting person retains 30,000 shares, transaction tied to corporate reorganization.
The Form 4 documents a non-cash, structural change rather than an open-market purchase or sale. The one-for-one conversion of Class B to Class A and then to common stock leaves the reporting person with 30,000 directly held common shares following the closing events on 08/11/2025. Because the filing reflects conversion under a business combination and domestication, it represents corporate housekeeping of equity records rather than a liquidity event. The director resignation effective immediately prior to domestication is a governance change investors may note but the filing does not provide reasons or additional compensatory details.
TL;DR: Governance and capitalization were adjusted via domestication; insider converted shares and resigned as director the same day.
The disclosure clarifies that Helix's Class B shares had no expiration date pre-conversion and converted one-for-one into Class A shares, and then into issuer common stock as part of the domestication process. The reporter's resignation as a director effective immediately prior to domestication is explicitly noted. This Form 4 is descriptive of structural corporate actions and resultant beneficial ownership; it contains no indication of sales, option exercises for cash, or additional change in voting arrangements beyond the conversions described.
Mark C. McKenna ha presentato un Modulo 4 segnalando variazioni nella titolarit脿 connesse alla business combination e alla domestication di Helix Acquisition Corp. II nell'emittente, identificata qui come BridgeBio Oncology Therapeutics, Inc. [BBOT]. In data 08/11/2025 le 30,000 azioni Helix di McKenna sono state convertite tramite uno scambio uno-a-uno da azioni ordinarie di Classe B in azioni ordinarie di Classe A e quindi in azioni ordinarie dell'emittente, con conseguente possesso beneficiario diretto di 30,000 azioni ordinarie. La comunicazione indica che la conversione 猫 avvenuta con una controprestazione pari a $0 nell'ambito della riorganizzazione societaria. Il dichiarante si 猫 inoltre dimesso dalla carica di direttore di Helix con effetto dalla medesima data, immediatamente prima della domestication.
Mark C. McKenna present贸 un Formulario 4 informando cambios en la propiedad vinculados a la combinaci贸n empresarial y la domestication de Helix Acquisition Corp. II en la emisora, identificada aqu铆 como BridgeBio Oncology Therapeutics, Inc. [BBOT]. El 08/11/2025 las 30,000 acciones de Helix de McKenna se convirtieron mediante un intercambio uno a uno de acciones ordinarias Clase B a Clase A y luego en acciones comunes de la emisora, resultando en la posesi贸n beneficiaria directa de 30,000 acciones comunes. La presentaci贸n indica que la conversi贸n se realiz贸 por una contraprestaci贸n de $0 como parte de la reorganizaci贸n corporativa. El declarante tambi茅n renunci贸 como director de Helix con efecto en la misma fecha, inmediatamente antes de la domestication.
Mark C. McKenna電� 氚滍枆須岇偓(鞐赴靹滊姅 BridgeBio Oncology Therapeutics, Inc. [BBOT])鞐� Helix Acquisition Corp. II鞚� 靷梾 瓴绊暕 氚� domestication瓿� 甏�霠悳 靻岇湢甓� 氤�瓴� 靷暛鞚� 氤搓碃頃橂姅 鞏戩嫕 4毳� 鞝滌稖頄堨姷雼堧嫟. 08/11/2025鞐� McKenna臧� 氤挫湢頃� Helix 欤检嫕 30,000欤茧姅 韥措灅鞀� B 氤错喌欤检棎靹� 韥措灅鞀� A 氤错喌欤茧 1:1 甑愴櫂霅� 頉� 氚滍枆須岇偓鞚� 氤错喌欤茧 鞝勴櫂霅橃柎, 攴� 瓴瓣臣 30,000欤检潣 氤错喌欤茧ゼ 歆侅爲鞝伮缝嫟歆堨爜鞙茧 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 鞚� 鞝勴櫂鞚� 須岇偓 鞛幐鞚� 鞚柬櫂鞙茧 $0鞚� 雽�臧�搿� 鞚措（鞏挫雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 鞝滌稖鞚胳潃 domestication 歆侅爠鞚� 臧欖潃 雮犾攵�搿� Helix鞚� 鞚挫偓歆侅棎靹� 靷瀯頄堨姷雼堧嫟.
Mark C. McKenna a d茅pos茅 un Formulaire 4 d茅clarant des changements de d茅tention li茅s 脿 la business combination et 脿 la domestication de Helix Acquisition Corp. II au sein de l'茅metteur, identifi茅 ici comme BridgeBio Oncology Therapeutics, Inc. [BBOT]. Le 08/11/2025, les 30,000 actions Helix de McKenna ont 茅t茅 converties via un 茅change un pour un d'actions ordinaires de classe B en actions ordinaires de classe A puis en actions ordinaires de l'茅metteur, ce qui aboutit 脿 la d茅tention b茅n茅ficiaire directe de 30,000 actions ordinaires. Le d茅p么t indique que la conversion a eu lieu pour une contrepartie de $0 dans le cadre de la r茅organisation d'entreprise. Le d茅clarant a 茅galement d茅missionn茅 de son poste d'administrateur de Helix 脿 la m锚me date, imm茅diatement avant la domestication.
Mark C. McKenna reichte ein Formular 4 ein, in dem 脛nderungen der Beteiligung im Zusammenhang mit der Business Combination und der domestication von Helix Acquisition Corp. II in den Emittenten, hier bezeichnet als BridgeBio Oncology Therapeutics, Inc. [BBOT], gemeldet werden. Am 08/11/2025 wurden McKennas 30,000 Helix-Aktien im Rahmen eines Eins-zu-eins-Tauschs von Class-B-Stammaktien in Class-A-Stammaktien und anschlie脽end in Stammaktien des Emittenten umgewandelt, wodurch er 30,000 vorteilhaft gehaltene Stammaktien direkt besitzt. Die Einreichung weist aus, dass die Umwandlung im Zuge der Unternehmensreorganisation ohne Gegenleistung in H枚he von $0 erfolgte. Der Einreicher trat au脽erdem mit Wirkung zum selben Datum, unmittelbar vor der domestication, als Direktor von Helix zur眉ck.
FAQ
What did Mark C. McKenna report on Form 4 for HLXB?
Why did the share class change occur according to the filing?
Did the reporting person sell any shares or receive cash in the transaction?
What director or governance changes are disclosed in the Form 4?
How many derivative securities remained after the conversion?
